Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Cuts 890 Jobs Since Beginning of 2011

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific has reduced its headcount by about 890 through the first nine months of the year, including 450 during the third quarter, it disclosed in it quarterly earnings document filed today with the US Securities and Exchange Commission.

The firm said in its 10-Q that the brunt of the reductions have occurred in its Laboratory Products and Services segment, where the number of employees have been lowered by 570 through three quarters, and by 260 in the third quarter.

In Analytical Technologies, the headcount reduction totaled 270 through the first nine months of the year and 180 in the third quarter, while the newly formed Specialty Diagnostics segment saw headcount reductions of 50 through three quarters and 10 in the third quarter.

Thermo Fisher has about 37,000 employees worldwide.

The company had alluded to layoffs and other headcount efforts during its third-quarter earnings conference call last week, with company officials saying that cost-reduction initiatives had been implemented to counter a slowdown in its academic/government end market, which accounts for about 24 percent of total revenues.

In addition to efforts already started, President and CEO Marc Casper said on the conference call that Thermo Fisher continues to "drive additional actions" in the fourth quarter and has put in place "very targeted share gain action plans to maximize our performance" in the Laboratory Product and Services segment, which has been most impacted by the academic/government business slowdown.

The initiatives have achieved about $30 million in annualized benefits, and in its SEC filing today Thermo Fisher said that as of Nov. 4 it has "identified restructuring actions that will result in additional charges of approximately $40 million in 2011 and expects to identify additional actions during the remainder of 2011. The restructuring actions initiated in the first nine months of 2011 are expected to result in annual cost savings of approximately $60 million."

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.